Main > > >BLADDER CANCER. *

---

Diagnostics. 15 DNA Methylation BioMar-
kers Urine Test.
EU Approval Date: 2017. 03.22.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.12.




Diagnostics. Blue Light Cystoscopy.
[non-muscle invasive bladder cancer (NMIBC)]
EU Approval Date: ?
Flexible Cystoscopes USA OK: 2018. 02.16
USA Approval Date: ?
USA Launch Date: 2018. 05.18.
PhotoSensitizer>HexaAminoLevulinate
(*) Company : PhotoCure ASA.
Patents : Expired on 2017. 12.05.
TradeMark : Cysview®
Web-Site : www.cysview.com/
UpDate: 2020. 03.29.




Diagnostics. Color+Morphology. Urine
Approved in EU & IL
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.12.




Diagnostics. Confocal Laser EndoMicros-
copy (CLE).
USA Approval Date: 2017. 12.18.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.08.




Diagnostics. FISH Urine Kit.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.12.




Diagnostics. Keratin 17 Urine Test.
EU CE Mark Date: 2020. 06.30.
(*) Company; Patent; TradeMark &
Web-Site Available on Request.
UpDate: 2021. 02.17.




Diagnostics. NMP POC Urine Test.
NMP: Nuclear Matrix Protein.
Status: Approved in EU & USA
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 06.12.




TREAT.: AtezolizuMAb.
(mUC: Metastatic Urothelial Cancer)
PD-L1 Inhibitor
CA Approval Date : 2017. 04.18.
USA Approval Date: 2016. 05.19.
USA Approval Date: 2017. 04.18.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.12.




TREAT.: AveluMAb.
(mUC: Metastatic Urothelial Cancer)
Human Anti-PD-L1 AB.
EU Approval Date: 2021. 01.25.
USA Approval Date: 2017. 05.09.
(*) Companies; TradeMark; USA Patent
APPs. & Web-Site Available on Re-
quest.
UpDate: 2021. 02.18.




TREAT.: Bacillus Calmette Guerin.
Approval Date: ?
(*) Company : Merck.
TradeMark: TICE® BCG
UpDate: 2018. 06.12.




TREAT.: EnfortuMAb Vedotin Inj. for IV
Infusion.>
(mUC: Metastatic Urothelial Cancer)
>Previously Received PD-1/L1 Inhibitor+
Pt ChemoTherapy.
After (Adjuvant) Surgery
Before (NeoAdjuvant) Surgery
EnfortuMAb: Nectin-4 MAb
Vedotin: MonoMe Auristatin E
USA Approval Date: 2019. 12.18.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2019. 12.23.




TREAT.: Erdafitinib.>
(mUC: Metastatic Urothelial Cancer)
>Has Susceptible FGFR2 or FGFR3 Genetic
Aberrations
>Have Progressed During or After At
Least One Line of Prior Pt-Contg CT,
including within 12 months of Neoad-
juvant or Adjuvant Pt-Contg. CT.
Companion Diagnostics>
>USA Launch Date: 2019. 04.12.
USA Approval Date: 2019. 04.12.
(*) Companies; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 04.13.




TREAT.: HyperThermia.
(Non-Muscle Invasive Bladder C.)
Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.12.




TREAT.: NivoluMAb
(mUC: Metastatic Urothelial Cancer)
USA Approval Date: 2017. 02.02.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.16.




TREAT.: PembrolizuMAb.
[Metastatic Urothelial Cancer (mUC)]
EU Approval Date : 2017. 09.05.
JP Approval Date : 2018. 01.02.
USA Approval Date: 2017. 05.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
Companion Diagnostics>
>USA Approval Date: 2018. 08.21.
>Company: Agilent Technologies.
UpDate: 2018. 08.22.




TREAT.: PembrolizuMAb.
[Non-Muscle Invasive Bladder Cancer (NMIBC)>with Carcinoma In Situ (CIS)>
Bacillus Calmette-Guerin (BCG)-UnRes-
posive]
USA Approval Date: 2020. 01.08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.10.


>BLADDER CANCER. *'s products
This section has no products